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Unilateral adrenocortical tumors consist in frequent benign adrenocortical adenomas (ACA) and rare 
malignant adrenocortical carcinomas (ACC). On one side, ACAs are among the most common human 
neoplasia with a reported prevalence of 2-10% in the general population. They are generally endocrine 
inactive and clinically unapparent, thus being often incidentally-discovered. However, in 30% of cases 
ACAs may be associated with autonomous steroid (cortisol or aldosterone) secretion and clinical 
syndromes that may induce severe morbidities and even increase mortality (1, 2). On the other side, 
ACC are extremely rare cancers with a usually aggressive clinical outcome (mean 5-year survival rate 
20-50%), mostly depending on initial tumour stage (3) and other clinical or histopathological 
parameters, such as the ki67 proliferation index (4, 5). For this reason it is important to precociously 
differentiate ACC from ACAs. Nowadays, the differential diagnosis mostly relies on a series of 
histopathological malignant criteria included in the Weiss score. Nevertheless, some cases still remain 
undefined (6), so that we are still looking for reliable diagnostic markers that may allow to precisely 
differentiate benign from malignant adrenocortical tumours. For instance, new techniques have been 
proposed, such as the urine steroid metabolome analysis (7), but their role in a routine setting needs to 
be validated. 
In recent years, thanks to collaborative efforts and technological advances, different research 
groups performed pan-genomic studies that allowed a significant improvement in knowledge of 
pathogenic mechanisms involved in adrenal tumour development and progression as well as in steroid 
autonomous secretion (8-11). For instance, in the field of ACA, somatic PRKACA mutations have 
been only recently reported to be involved in the pathogenesis of 35-65% of cortisol-producing 
adenomas (CPA) associated with overt Cushing syndrome (12). Thanks to this finding, we are now 
aware that the pathogenesis of up to 60% of CPA is due to genetic alterations in the cAMP/PKA 
pathway (i.e. affecting PRKACA and GNAS genes). Moreover, somatic mutations in KCNJ5 (K+ 
channel), ATP1A1 (Na+K+-ATPase), ATP2B3 (Ca2+-ATPase) and CANCA1D (Ca2+ channel, L type), 
have been recently found to be associated with the pathogenesis of 40-70% of aldosterone-producing 
adenomas (APA) (13).  
Despite these important improvements in terms of molecular pathogenesis, many clinically-
relevant questions on ACA still remain unanswered. For instance: How can we accurately diagnose 
the presence of a clinically unapparent (“subclinical” or mild) cortisol excess (Cushing syndrome) in 
patients affected by CPA? Which are the clinical implications and consequences of the presence of 
autonomous cortisol secretion in absence of overt clinical symptoms? Which are the best strategies for 
the management of patients with incidentally discovered endocrine inactive adenomas or with 
“subclinical” CPA?  
Considering the ACC, novel genetic alterations have been discovered to be involved in their 
pathogenesis (e.g. in genes ZNRF3, DAXX, TERT, MED12, PRKAR1A, RPL22, TERF2, CCNE1, and 
NF1) and/or associated with more aggressive behaviour and worst prognosis (8, 9). However, fully 
reliable and easy-applicable clinical and molecular prognostic factors for patients with ACC are still 
missing. In addition, up to date, only few pharmacological treatments are available for patients with 
advanced ACC. Some previous studies aimed to identify potential drug targets that might be useful for 
innovative therapeutic approaches in patients with advanced ACC, unfortunately without satisfying 
results (14, 15). On this connection, a very recent paper from our group demonstrated that targeted 
molecular profiling of tumor samples on formalin-fixed paraffin-embedded specimens is feasible and 
able to simultaneously improve prognostication of ACC beyond clinical/histopathological parameters 
and identify new potential drug targets (16). These findings might then pave the way to a precision 
medicine approach to ACC.  
To summarise, basic and translational research on adrenocortical tumors is an active field that 
generated very promising advances during the last few years. Prominent examples include an 
improved understanding of adrenal tumor molecular pathogenesis as well as the introduction of new 
potential diagnostic and prognostic biomarkers. International collaboration as well as the use of 
innovative technology will be key factors to accelerate improvements in our knowledge of pathogenic 
mechanisms and in our skills for better diagnosis, prognosis and treatment of patients with these 
tumors. This will be possible only through joint efforts especially both within the European (European 
Network for the Study of Adrenocortical Tumours ENSAT, http://www.ensat.org/) and the extra-
European community (The American-Australian-Asian Adrenal Alliance A5, 
https://elselab.wordpress.com/a5/). However, at the moment, routine management strategy for 
adrenocortical tumours might be challenging in several steps and should be decided in the setting of a 
multidisciplinary team in expert centers. 
In this special issue, we present a number of systemic reviews focusing on the state-of-the-art 
about pathogenesis, diagnosis, prognosis and treatment of unilateral adrenocortical tumours focusing 
on non-aldosterone-producing ones. The Authors also give specific insights into future approaches 
proposed to improve the management of patients with adrenocortical tumours.  
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